Effect of treatment on the evolution of renal abnormalities in lupus nephritis

scientific article published on 01 August 1984

Effect of treatment on the evolution of renal abnormalities in lupus nephritis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM198408233110802
P698PubMed publication ID6749206

P50authorAlfred D SteinbergQ117315555
P2093author name stringKlippel JH
Balow JE
Decker JL
Plotz PH
Muenz LR
Joyce KM
Antonovych TT
Austin HA 3rd
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectlupus nephritisQ1621830
P304page(s)491-495
P577publication date1984-08-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleEffect of treatment on the evolution of renal abnormalities in lupus nephritis
P478volume311

Reverse relations

cites work (P2860)
Q69773257Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis
Q33746862Anti-DNA autoantibodies and systemic lupus erythematosus
Q79839545Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial
Q87393398Chapter 12: Lupus nephritis
Q87393403Chapter 14: Anti-glomerular basement membrane antibody glomerulonephritis
Q35579156Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation
Q57011999Clinical and prognostic value of serial renal biopsies in lupus nephritis
Q70031023Clinical significance of U1-RNP immune complexes in mixed connective tissue disease and systemic lupus erythematosus
Q69259494Clinical significance of renal biopsies showing mixed mesangial and global proliferative lupus nephritis
Q34309764Combination treatment in autoimmune diseases: systemic lupus erythematosus.
Q69552546Correlation of renal histology with outcome in children with lupus nephritis
Q77798502Current role of renal biopsy in patients with SLE
Q37949332Current treatment recommendations for lupus nephritis
Q36711562Cyclophosphamide toxicity. Characterising and avoiding the problem
Q35087985Dexamethasone induces connective tissue growth factor expression in renal tubular epithelial cells in a mouse strain-specific manner
Q41226267Effect of long-term normalization of serum complement levels on the course of lupus nephritis
Q54395791Effects of cyclosporine in severe systemic lupus erythematosus.
Q40465520Glomerular thrombosis predicts progression of glomerulonephritis: Can we prevent progression?
Q42479257Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells
Q40883177Immunosuppressive drug therapy in lupus nephritis
Q35547376Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide
Q40828770Indications for, and use of, cytotoxic agents in SLE.
Q64113375Innate Immune Cells' Contribution to Systemic Lupus Erythematosus
Q73407589Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
Q54352606Intermittent intravenous cyclophosphamide therapy for lupus nephritis.
Q52886016Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group.
Q36302245Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Q36840240Kidney disease in systemic lupus erythematosus
Q73604873Lupus nephritis
Q40665188Lupus nephritis in childhood and adolescence
Q69420359Lupus nephritis. Middlesex, October 20, 1988. Abstracts
Q67299868Lupus nephritis: more answers needed
Q33614633New approaches to treating systemic lupus erythematosus
Q35039863Newer drugs for the treatment of lupus nephritis
Q35814458Outcome of the acute glomerular injury in proliferative lupus nephritis
Q68145720Pemphigus
Q36748174Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data
Q46839690Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group
Q40506590Prognosis in systemic lupus erythematosus
Q33286668Prognostic factors in systemic lupus erythematosus
Q57945954References
Q68591107Renal biopsy
Q67560104Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group
Q35595464Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease
Q67730594Severe recurrent lupus laryngitis
Q42148555Stem cell transplantation: limits and hopes
Q68862114Systemic lupus erythematosus
Q40506580Systemic lupus erythematosus--disease management
Q38791636The treatment of lupus nephritis
Q34731092Therapy of systemic lupus erythematosus: a look into the future
Q72002018Treatment of lupus glomerulonephritis with intravenous cyclophosphamide
Q37822658Treatment of proliferative lupus nephritis: a slowly changing landscape
Q74022703Treatment of systemic lupus erythematosus
Q36840264Treatment of systemic lupus erythematosus: which options do we have for therapy regimens?
Q34403507Treatment of vasculitis
Q33893383Update on cyclophosphamide for systemic lupus erythematosus

Search more.